Badges [ 5 ] [-]
Memberships [ 1 ] [+]
Activity Stream [+]
Ideas Contributed [ 3 ] [+]
Novel blood products are being developed based on innovative science (e.g., ex vivo manufactured RBC and platelets, and platelet and plasma derived hemostatic products). However, there is a significant lag in the development of appropriate tools and model systems, which poses a challenge when evaluating such products for regulatory approval.
There is a compelling need to advance research to understand the physiology governing the safety and efficacy of hemoglobin-based oxygen therapeutics functioning outside the red cell.
There is a critical need for a proactive and coordinated effort to develop well-characterized biorepositories that can be used for epidemiologic studies of emerging infectious agents to expedite rapid implementation of donor screening tests for emerging pathogens and variants that pose a threat to the blood supply.